Thomas W. LeBlanc

10.9k total citations · 4 hit papers
330 papers, 5.5k citations indexed

About

Thomas W. LeBlanc is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Thomas W. LeBlanc has authored 330 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Public Health, Environmental and Occupational Health, 154 papers in Oncology and 111 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Thomas W. LeBlanc's work include Palliative Care and End-of-Life Issues (156 papers), Cancer survivorship and care (108 papers) and Childhood Cancer Survivors' Quality of Life (104 papers). Thomas W. LeBlanc is often cited by papers focused on Palliative Care and End-of-Life Issues (156 papers), Cancer survivorship and care (108 papers) and Childhood Cancer Survivors' Quality of Life (104 papers). Thomas W. LeBlanc collaborates with scholars based in United States, United Kingdom and Canada. Thomas W. LeBlanc's co-authors include Amy P. Abernethy, Areej El‐Jawahri, Arif H. Kamal, Jennifer S. Temel, David C. Currow, Eric Roeland, Steven Wolf, Susan C. Locke, Lara Traeger and Joseph A. Greer and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Thomas W. LeBlanc

303 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

2015 422 citations Holly G. Prigerson, Manish A. Shah et al. profile →
Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation

2016 289 citations Areej El‐Jawahri, Thomas W. LeBlanc et al. profile →
Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline

2022 139 citations Thomas W. LeBlanc et al. Journal of Clinical Oncology profile →
Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline

2022 109 citations Areej El‐Jawahri, Thomas W. LeBlanc et al. Journal of Clinical Oncology profile →

Peers

Thomas W. LeBlanc

PHEOH

ONCOL

PPCH

GHP

HEMAT

Arif H. Kamal United States

Victor T. Chang United States

Massimo Costantini Italy

Gregory A. Abel United States

Deborah K. Mayer United States

Alison Richardson United Kingdom

Gary B. Chisholm United States

Antonia V. Bennett United States

Maura K. Whiteman United States

Emma Ream United Kingdom

Arif H. Kamal United States

Thomas W. LeBlanc

2.7k ×0.8

PHEOH

1.3k ×0.5

ONCOL

1.2k ×0.5

PPCH

1.1k ×1.5

GHP

223 ×0.4

HEMAT

Citations per year, relative to Thomas W. LeBlanc Thomas W. LeBlanc (= 1×) peers Arif H. Kamal

Countries citing papers authored by Thomas W. LeBlanc

Since Specialization

Citations

This map shows the geographic impact of Thomas W. LeBlanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas W. LeBlanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas W. LeBlanc more than expected).

Fields of papers citing papers by Thomas W. LeBlanc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas W. LeBlanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas W. LeBlanc. The network helps show where Thomas W. LeBlanc may publish in the future.

Co-authorship network of co-authors of Thomas W. LeBlanc

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas W. LeBlanc. A scholar is included among the top collaborators of Thomas W. LeBlanc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas W. LeBlanc. Thomas W. LeBlanc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Locke, Susan C., Jesse D. Troy, Laura Iadeluca, et al.. (2025). Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis. Clinical Lymphoma Myeloma & Leukemia. 25(8). e570–e579.e4.

LeBlanc, Thomas W., et al.. (2025). Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research. 14(5). e240236–e240236. 1 indexed citations

LeBlanc, Thomas W., et al.. (2025). Early Specialist Palliative Care in Patients with Metastatic Cancer: A Population-Based Cohort Study. Journal of Pain and Symptom Management. 70(2). 140–148.e2.

El‐Jawahri, Areej, Joseph A. Greer, Vicki A. Jackson, et al.. (2024). Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.. Journal of Clinical Oncology. 42(17_suppl). LBA6508–LBA6508.

Fortune, Erica E., et al.. (2023). Measuring Social Toxicity in Acute Myeloid Leukemia. Blood. 142(Supplement 1). 5182–5182. 1 indexed citations

Barata, Anna, Hannah R. Abrams, Lih‐Wen Mau, et al.. (2023). What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients. Blood Advances. 7(10). 2032–2041. 6 indexed citations

Schwartzberg, Lee S., Rudolph M. Navari, Kathryn J. Ruddy, et al.. (2023). Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Supportive Care in Cancer. 31(11). 654–654. 1 indexed citations

LeBlanc, Thomas W., et al.. (2023). A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma. Current Medical Research and Opinion. 40(2). 199–207. 8 indexed citations

Rosa, William E., Shigeko Izumi, Donald R. Sullivan, et al.. (2022). Advance Care Planning in Serious Illness: A Narrative Review. Journal of Pain and Symptom Management. 65(1). e63–e78. 59 indexed citations

10.

Porter, Laura S., Diane L. Fairclough, Thomas W. LeBlanc, et al.. (2021). Caregiver-guided pain coping skills training for patients with advanced cancer: Results from a randomized clinical trial. Palliative Medicine. 35(5). 952–961. 18 indexed citations

11.

Johnson, P. Connor, Matthew Reynolds, Jason A. Webb, et al.. (2021). Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia. Journal of Palliative Medicine. 25(5). 749–756. 9 indexed citations

12.

Pelcovits, Ari, et al.. (2021). Impact of Early Palliative Care on End-of-Life Outcomes in Hematologic Malignancies. Journal of Palliative Medicine. 25(4). 556–561. 8 indexed citations

13.

Suh, Sang‐Yeon, Yusuke Hiratsuka, Sung‐Eun Choi, et al.. (2021). Assessment of Changes in Symptoms Is Feasible and Prognostic in the Last Weeks of Life: An International Multicenter Cohort Study. Journal of Palliative Medicine. 25(3). 388–395. 5 indexed citations

14.

Dhawan, Natasha & Thomas W. LeBlanc. (2021). Lean Into the Uncomfortable: Using Trauma-Informed Care to Engage in Shared Decision-Making With Racial Minorities With Hematologic Malignancies. American Journal of Hospice and Palliative Medicine®. 39(1). 4–8. 8 indexed citations

15.

Bélanger, Emmanuelle, et al.. (2020). Early Palliative Care Services and End-of-Life Care in Medicare Beneficiaries with Hematologic Malignancies: A Population-Based Retrospective Cohort Study. Journal of Palliative Medicine. 24(1). 63–70. 18 indexed citations

16.

Resick, Judith, Robert M. Arnold, Thomas W. LeBlanc, et al.. (2020). Primary Palliative Care for Patients with Advanced Hematologic Malignancies: A Pilot Trial of the SHARE Intervention. Journal of Palliative Medicine. 24(6). 820–829. 11 indexed citations

17.

Derry, Heather M., Paul K. Maciejewski, Andrew S. Epstein, et al.. (2019). Associations between Anxiety, Poor Prognosis, and Accurate Understanding of Scan Results among Advanced Cancer Patients. Journal of Palliative Medicine. 22(8). 961–965. 24 indexed citations

18.

Loh, Kah Poh, Huiwen Xu, Anthony L. Back, et al.. (2019). Patient‐hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study. Cancer. 126(6). 1306–1314. 21 indexed citations

19.

Chino, Fumiko, Arif H. Kamal, Thomas W. LeBlanc, et al.. (2018). Place of death for patients with cancer in the United States, 1999 through 2015: Racial, age, and geographic disparities. Cancer. 124(22). 4408–4419. 45 indexed citations

20.

Samsa, Gregory P., Thomas W. LeBlanc, Aimee K. Zaas, Lynn Howie, & Amy P. Abernethy. (2014). Designing a Course in Statistics for a Learning Health Systems Training Program. 14(3). 55–67. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact